期刊文献+

DNA修复基因XPD 312 Asn和751Lys多态性与非吸烟女性肺癌的关系 被引量:1

Association of genetic polymorphism in the DNA repair gene XPD and risk of lung cancer in non-smoking females
下载PDF
导出
摘要 目的 着色性干皮病互补基因D(xeroderma pigmentosum group D,XPD)是一种重要的DNA损伤修复基因,其常见的多态是位于751密码子的A→C颠换和312密码子G→A转换.本研究旨在探讨XPD基因751位点和312位点单核苷酸多态性与非吸烟女性肺癌易感性的关系.方法 采用病例-对照研究方法,纳入非吸烟女性肺癌患者222人和对照222人.以聚合酶链反应-限制性片段长度多态性方法分析XPD基因Lys751Gln和Asp312Asn多态基因型.结果 携带至少1个751Gln等位基因者和携带至少1个312Asn等位基因者患肺癌的风险均显著增高,调整OR分别为3.36(95%CI为2.29-4.90)和1.83(95%CI为1.16-2.91).结论 XPD基因Lys751Gln和Asp312Asn多态是非吸烟女性肺癌的遗传易感因素. Objective Xeroderma pigmentosum group D (XPD)is one of the important DNA repair genes. XPD polymorphism at Lys751 Gin site and Asp312Ash site have been shown to alter XPD protein function, modulate DNA repair capacity and therefore affect cancer risk. The aim of this study is to explore the relationship between XPD polymorphism and susceptibility to lung cancer in nonsmoking female by a population - based case -control study. Methods There were 222 female patients who were diagnosed with lung cancer from Heilongjiang Tumor Hospital, and the control group included 222 healthy volunteers who were obtained from community centers. XPD genotypes of cases and controls were determined by PCR RFLP method. Unconditional logistic regression analysis was performed to calculate the odds ratios (OR)with 95 confidence intervals (CI)for estimating the association between certain genotypes and lung cancer. Results All of the subjects in this study were nonsmoking females who living in Harbin more than 30 years. The risk of lung cancer was higher in those with the Lys/Gln or Gin/Gin genotype than in those with the Lys/Iys genotype and adjusted OR was 3.36(95 CI:2.29 - 4.90) and in those with the Asn/Asn or Asp/Asn genotype than in those with the Asp/Asp genotype and adjusted OR was 1.83(95 CI: 1.16 - 2.91 ). Conclusion The findings indicated that the Lys751Gln and Asp312Asn polymorphisms in XPD gene are associated with the risk of lung cancer in nonsmoking females.
出处 《实用肿瘤学杂志》 CAS 2010年第2期108-111,共4页 Practical Oncology Journal
基金 国家自然基金项目资助(30371244) 黑龙江省卫生厅项目资助(2005-212)
关键词 女性肺癌 XPD基因 遗传多态性 Female lung cancer XPD gene Genetic polymorphism
  • 相关文献

参考文献14

二级参考文献45

  • 1[1]Le Marchand L, Sivaraman L, Pierce L, et al. Associations of CYP1A1, GSTM1, and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res,1998,58(21):4858-4863. 被引量:1
  • 2[2]Cascorbi I, Brockmoller J, Roots I. A C4887A polymorphism in exon 7 of human CYP1A1: population frequency, mutation linkages, and impact on lung cancer susceptibility. Cancer Res,1996,56(21):4965-4969. 被引量:1
  • 3[3]Kihara M, Kihara M, Noda K. Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations of CYP1A1 and GSTM1 gene polymorphisms in a Japanese population. Carcinogenesis,1995,16(10):2331-2336. 被引量:1
  • 4[4]Deutsch-Wenzel RP, Brune H, Grimmer G, et al. Experimental studies in rat lungs on the carcinogenicity and dose-response relationships of eight frequently occurring environmental polycyclic aromatic hydrocarbons. J Natl Cancer Inst,1983,71(3):539-544. 被引量:1
  • 5[5]Song N, Tan W, Xing D, et al. CYP 1A1 polymorphism and risk of lung cancer in relation to tobacco smoking: a case-control study in China. Carcinogenesis,2001,22(1):11-16. 被引量:1
  • 6[6]Yokoi T, Kamataki T. Genetic polymorphism of drug metabolizing enzymes: new mutations in CYP2D6 and CYP2A6 genes in Japanese. Pharm Res,1998,15(4):517-524. 被引量:1
  • 7[8]Le Marchand L, Wilkinson GR, Wilkens LR. Genetic and dietary predictors of CYP2E1 activity: a phenotyping study in Hawaii Japanese using chlorzoxazone. Cancer Epidemiol Biomarkers Prev,1999,8(6):495-500. 被引量:1
  • 8Wood RD, et al. [J]. Science, 2001, 291(5507) : 1284-1289. 被引量:1
  • 9Ronen A, et al. [J]. Environ Mol Mut, 2001,37(3) :241-283. 被引量:1
  • 10Caldecott KW, et al. [J]. Nucleic Acids Res,1996, 24(22) :4387-4394. 被引量:1

共引文献97

同被引文献15

  • 1李体远 ,Jing Jie yu ,Eddie Reed .卵巢癌细胞ERCC1基因VIII外显子剪接变异及功能研究[J].中国实验诊断学,2004,8(4):419-423. 被引量:8
  • 2Kelly K,Crowley J,Bunn PA. Randomized phase Ⅲ trial of paclitaxel plus carboplatin versus vinorelbie plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer:a Southwest Oncology Group trial[J].Clinical Oncology,2001.3210-3218. 被引量:1
  • 3Scagliotti GV,De Marinis F,Rinaldi M. Phase Ⅲ randomized trial comparing three platinum-based doublets in advanced non-small-cell lung cancer[J].Clinical Oncology,2002.4285-4291.doi:10.1200/JCO.2002.02.068. 被引量:1
  • 4Rajeswaran A,Trojan A,Burnand B. Efficacy and side effects of cisplatin and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma:a systematic review of randomized controlled trials[J].Lung Cancer,2008,(01):1-11.doi:10.1016/j.lungcan.2007.07.012. 被引量:1
  • 5Kalikaki A,Kanaki M,Vassalou H. DNA repair gene polymorphisms predict favorable clinical outcme in advanced non-small-cell lung cancer[J].Clinical Lung Cancer,2009,(02):118-223. 被引量:1
  • 6Jeong SR,Yun CH,Hye SH. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy[J].Lung Cancer,2004.311-316. 被引量:1
  • 7Li F,Sun XC,Sun N. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer[J].American Journal of Clinical Oncology,2010,(05):489-494. 被引量:1
  • 8Ryu JS,Hong YC,Han HS. Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy[J].Lung Cancer,2004,(03):311-316.doi:10.1016/j.lungcan.2003.11.019. 被引量:1
  • 9Richard B,Tim W,Jim H. Xeroderma pigmentosum group D haplotype predicts for response,survival,and toxicity after platinum based chemotherapy in advanced nonsmall cell lung cancer[J].American Cancer Society Inc,2006.2421-2427. 被引量:1
  • 10Stoehlmacher J,Park DJ,Zhang W. A multivariate analysis of genomic polymorphisms:prediction of clinical outcome to 5-FU/oxaliplatin combination chemotherapy in refractory colorectal cancer[J].British Journal of Cancer,2004.344-354. 被引量:1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部